Table of Content

1. Executive Summary
• Introduction
2. Head and Neck Cancer: Overview
• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment
3. Pipeline Analysis
• Assessment by Phase
o Phase I Clinical Trials
o Phase II Clinical Trials
o Phase III Clinical Trials
• Assessment by Mechanism of Action
o Immunotherapy
o Targeted Therapies
o Chemotherapy
o Radiation Therapy
o Combination Therapy
o Others
• Assessment by Route of Administration
o Intravenous
o Oral
o Topical
4. List of Key Companies Involved
• Merck & Co., Inc.*
o Detailed Drug Profile
• GlaxoSmithKline
• Rakuten Medical, Inc.
• Incyte Corporation
• Adlai Nortye Biopharma Co., Ltd.
• Merus N.V.
• Akeso Biopharma Co., Ltd.
• Coordination Pharmaceuticals, Inc.
• QBiotics Group Limited
• Psivac Ltd
• BioNTech SE
• Pfizer Inc.
• Ascendis Pharma A/S
• Shanghai Henlius Biotech
• Fulgent Pharma LLC.
5. Regulatory Designations
• Orphan Drug Designation
• Fastrack Designation
• Breakthrough Therapy Designation
• Priority Review
• PRIME Designation
• RMAT Designation
• ATMP Designation
6. Clinical Data Readouts
• Trial Initiation
• Trial Completion
• Safety/Efficacy- Data Readouts
• Discontinued Products
7. Estimated Approvals
8. Merger and Acquisitions
9. Future Perspectives and Conclusion